EGFR and non-small cell lung carcinoma: Erlotinib with/without INC280 compared with platinum plus pemetrexed, in patients with EGFR TKI-resistant NSCLC due to cMET amplification (EGFR T790M-negative) [Ongoing Phase Ib/II study]